Quantification and Characterization of Circulating Epithelial and Endothelial Cells in Gougerot-Sjögren Syndrome, Compared to Systemic Sclerosis (CIRCEE)
Primary Purpose
Primary Gougerot-Sjögren Syndrome, Systemic Sclerosis, Diffuse
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood sampling
Sponsored by
About this trial
This is an interventional other trial for Primary Gougerot-Sjögren Syndrome focused on measuring Sjögren's syndrome, systemic sclerosis, progenitor cells, circulating endothelial cells, circulating epithelial cells, endothelium, epithelium, autoimmune diseases, connective tissue disorders
Eligibility Criteria
Inclusion Criteria:
- Female patients over the age of 18
- Written and signed consent by the participant and the investigator
- Affiliated person or beneficiary of the social security system
- Test group: patients with Gougerot-Sjögren's syndrome connectivitis meeting the ACR/EULAR classification criteria
- Positive control group: patients with diffuse systemic scleroderma connectivitis meeting ACR/EULAR classification criteria
Exclusion Criteria:
- Association of the two diseases in the same patient
- Progressive cancer
- Subject protected by law, under guardianship or curatorship
- Inability to give free and informed consent to participate in the study
- Withdrawal of consent
Sites / Locations
- Montpellier University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Experimental group
Positive control group
Arm Description
Patients with Gougerot-Sjögren's syndrome meeting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) disease definitions
Patients with diffuse systemic scleroderma meeting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) disease definitions
Outcomes
Primary Outcome Measures
Circulating epithelial cell detection rate
Rate of patients with at least 1 circulating epithelial cell in the peripheral blood
Secondary Outcome Measures
Number of circulating epithelial cells
Number of circulating epithelial cells expressing human epidermal growth factor receptor 2 (HER2)
Number of circulating epithelial and endothelial cells
Full Information
NCT ID
NCT05528809
First Posted
September 1, 2022
Last Updated
October 22, 2022
Sponsor
University Hospital, Montpellier
1. Study Identification
Unique Protocol Identification Number
NCT05528809
Brief Title
Quantification and Characterization of Circulating Epithelial and Endothelial Cells in Gougerot-Sjögren Syndrome, Compared to Systemic Sclerosis
Acronym
CIRCEE
Official Title
Quantification and Characterization of Circulating Epithelial and Endothelial Cells in Gougerot-Sjögren Syndrome, Compared to Systemic Sclerosis
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 12, 2022 (Actual)
Primary Completion Date
October 1, 2023 (Anticipated)
Study Completion Date
October 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Primary Gougerot-Sjögren's syndrome is a systemic autoimmune disease belonging to the group of connectivities, whose physiopathology remains largely unknown. Quantification and characterization of epithelial and endothelial circulants in Gougerot-Sjögren's syndrome could reflect the intensity of the epithelial aggression, and thus possibly constitute a biomarker.
Detailed Description
Primary Gougerot-Sjögren's syndrome is a systemic autoimmune disease belonging to the group of connectivities.
The criteria for classification of the disease include dry syndrome, positive salivary gland biopsy and detection of anti-Sjögren's-syndrome-related antigen A (anti-SSA) and anti-Sjögren's-syndrome-related antigen B (anti-SSB) antibodies. The presence of antibodies is thus important for the diagnosis but not essential, because in some patients the salivary gland biopsy is positive and the antibodies are absent. Therefore, the identification of new biomarkers could be very useful to confirm the diagnosis of primary Gougerot-Sjögren's syndrome and to identify subgroups of patients.
The pathophysiology of the disease remains largely unknown. Currently, primary Gougerot-Sjögren's syndrome is thought to originate from inflammation of the epithelial tissue of the salivary glands. However, it is currently unknown whether this autoimmune epithelitis is accompanied by a contingent of circulating epithelial cells, the characterization of which might be accessible by liquid biopsy.
So far, the circulating epithelial cells that have been identified have been identified in the context of cancer: in this case they are called circulating tumor cells. Their detection during primary Gougerot-Sjögren's syndrome could reflect the intensity of epithelial aggression, and thus possibly constitute a biomarker.
In other connectivities, data on circulating cells have already been published. In systemic scleroderma, another connectivitis affecting mainly middle-aged women, circulating progenitor cells have already been detected and are thought to have the capacity to differentiate into endothelial cells, thus playing a potentially important role in the pathophysiology of the disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Gougerot-Sjögren Syndrome, Systemic Sclerosis, Diffuse
Keywords
Sjögren's syndrome, systemic sclerosis, progenitor cells, circulating endothelial cells, circulating epithelial cells, endothelium, epithelium, autoimmune diseases, connective tissue disorders
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This a single-center prospective comparative non-randomized cohort pilot study, with 2 parallel groups (experimental group : patients with Gougerot-Sjögren's syndrome and positive control group : patients with diffuse systemic scleroderma).
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Experimental group
Arm Type
Experimental
Arm Description
Patients with Gougerot-Sjögren's syndrome meeting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) disease definitions
Arm Title
Positive control group
Arm Type
Active Comparator
Arm Description
Patients with diffuse systemic scleroderma meeting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) disease definitions
Intervention Type
Other
Intervention Name(s)
Blood sampling
Intervention Description
A blood sampling will be performed during the inclusion visit (day 0).
Primary Outcome Measure Information:
Title
Circulating epithelial cell detection rate
Description
Rate of patients with at least 1 circulating epithelial cell in the peripheral blood
Time Frame
day 0
Secondary Outcome Measure Information:
Title
Number of circulating epithelial cells
Time Frame
day 0
Title
Number of circulating epithelial cells expressing human epidermal growth factor receptor 2 (HER2)
Time Frame
day 0
Title
Number of circulating epithelial and endothelial cells
Time Frame
day 0
10. Eligibility
Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female patients over the age of 18
Written and signed consent by the participant and the investigator
Affiliated person or beneficiary of the social security system
Test group: patients with Gougerot-Sjögren's syndrome connectivitis meeting the ACR/EULAR classification criteria
Positive control group: patients with diffuse systemic scleroderma connectivitis meeting ACR/EULAR classification criteria
Exclusion Criteria:
Association of the two diseases in the same patient
Progressive cancer
Subject protected by law, under guardianship or curatorship
Inability to give free and informed consent to participate in the study
Withdrawal of consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Philippe GUILPAIN, MD, PhD
Phone
+33 4 67 33 73 32
Email
p-guilpain@chu-montpellier.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Stéphanie HERMABESSIERE
Phone
+33 4 67 33 73 32
Email
s-hermabessiere@chu-montpellier.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philippe GUILPAIN, MD, PhD
Organizational Affiliation
University Hospital, Montpellier
Official's Role
Principal Investigator
Facility Information:
Facility Name
Montpellier University Hospital
City
Montpellier
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe Guilpain, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Quantification and Characterization of Circulating Epithelial and Endothelial Cells in Gougerot-Sjögren Syndrome, Compared to Systemic Sclerosis
We'll reach out to this number within 24 hrs